Conventional EPO leads to an activation of blood coagulation, platelet hyperactivity, hypertension and hyper viscosity after activation of the EPO-R18, and has been clinically associated with an increased risk of thromboembolism35, –37, especially in non-anemic patients. This evidence concerns the gene EPO and hypertensive disorder.